What was the overall market valuation of the US osteoporosis drugs market in 2024?

The overall market valuation was $2720.0 Million in 2024. Read More

What is the projected market valuation for the US osteoporosis drugs market by 2035?

The projected market valuation for 2035 is $4730.0 Million. Read More

What is the expected CAGR for the US osteoporosis drugs market during the forecast period 2025 - 2035?

The expected CAGR for the market during 2025 - 2035 is 5.16%. Read More

Which drug class had the highest valuation in the US osteoporosis drugs market in 2024?

In 2024, Bisphosphonates had the highest valuation at $1300.0 Million. Read More

What are the projected valuations for Calcium and Vitamin D Supplements by 2035?

The projected valuations for Calcium and Vitamin D Supplements range from $600.0 Million to $1000.0 Million. Read More

Which route of administration is expected to generate the highest revenue in the US osteoporosis drugs market?

Oral administration is expected to generate the highest revenue, with a projected range of $1080.0 Million to $1880.0 Million. Read More

What was the valuation range for the retail pharmacy distribution channel in 2024?

The valuation range for the retail pharmacy distribution channel was $1080.0 Million to $1900.0 Million in 2024. Read More

Which patient population segment is projected to have the highest market valuation by 2035?

Postmenopausal women are projected to have the highest market valuation, ranging from $1360.0 Million to $2390.0 Million. Read More

Who are the key players in the US osteoporosis drugs market?

Key players include Amgen, Bristol-Myers Squibb, Novartis, Merck & Co., Sanofi, Pfizer, Eli Lilly and Company, Teva Pharmaceutical Industries, and Horizon Therapeutics. Read More

What is the projected valuation for the intravenous route of administration by 2035?

The projected valuation for the intravenous route of administration ranges from $680.0 Million to $1200.0 Million by 2035. Read More

US Osteoporosis Drugs Market

ID: MRFR/Pharma/16455-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Osteoporosis Drugs Market Research Report: Size, Share, Trend Analysis By Drug Type (Bisphosphonates, Hormone Replacement Therapy, Selective Estrogen Receptor Modulators, Denosumab, Parathyroid Hormone), By Route of Administration (Oral, Intravenous, Subcutaneous), By Applications (Postmenopausal Osteoporosis, Osteoporosis in Men, Glucocorticoid-Induced Osteoporosis) and By End Use (Hospitals, Homecare, Research Laboratories) - Growth Outlook & Industry Forecast 2025 To 2035

US Osteoporosis Drugs Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Drug Class (USD Million)
  1. 4.1.1 Bisphosphonates
  2. 4.1.2 Hormonal Therapy
  3. 4.1.3 Monoclonal Antibodies
  4. 4.1.4 Calcium and Vitamin D Supplements
  5. 4.1.5 Selective Estrogen Receptor Modulators
2. 4.2 Chemicals and Materials, BY Route of Administration (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Intravenous
  3. 4.2.3 Subcutaneous
  4. 4.2.4 Transdermal
3. 4.3 Chemicals and Materials, BY Distribution Channel (USD Million)
  1. 4.3.1 Hospital Pharmacy
  2. 4.3.2 Retail Pharmacy
  3. 4.3.3 Online Pharmacy
4. 4.4 Chemicals and Materials, BY Patient Population (USD Million)
  1. 4.4.1 Postmenopausal Women
  2. 4.4.2 Men
  3. 4.4.3 Elderly Population
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Amgen (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novartis (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck & Co. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Eli Lilly and Company (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Teva Pharmaceutical Industries (IL)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Horizon Therapeutics (IE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DRUG CLASS
3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 US MARKET ANALYSIS BY PATIENT POPULATION
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY PATIENT POPULATION, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY PATIENT POPULATION, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  4. 7.2.4 BY PATIENT POPULATION, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Drug Class (USD Million, 2025-2035)

Bisphosphonates
Hormonal Therapy
Monoclonal Antibodies
Calcium and Vitamin D Supplements
Selective Estrogen Receptor Modulators

Chemicals and Materials By Route of Administration (USD Million, 2025-2035)

Oral
Intravenous
Subcutaneous
Transdermal

Chemicals and Materials By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Chemicals and Materials By Patient Population (USD Million, 2025-2035)

Postmenopausal Women
Men
Elderly Population

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”